These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25855012)

  • 21. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
    Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
    Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HSP90 inhibitors in lung cancer: promise still unfulfilled.
    Chatterjee S; Bhattacharya S; Socinski MA; Burns TF
    Clin Adv Hematol Oncol; 2016 May; 14(5):346-56. PubMed ID: 27379696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
    Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heat shock protein 90 inhibition in lung cancer.
    Shimamura T; Shapiro GI
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S152-9. PubMed ID: 18520302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat shock protein antagonists in early stage clinical trials for NSCLC.
    Hendriks LEL; Dingemans AC
    Expert Opin Investig Drugs; 2017 May; 26(5):541-550. PubMed ID: 28274158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.